Roco Weight Loss: What It Is, How It Works, and Whether the Compounded Version Delivers Results

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Roco is a marketing name for compounded semaglutide sold through select telehealth platforms, not a distinct drug or FDA-approved product
• The active ingredient is identical to Ozempic and Wegovy (semaglutide), but compounded versions are prepared by pharmacies rather than manufactured by Novo Nordisk
• Clinical trial data shows semaglutide produces 15-17% total body weight loss over 68 weeks at the 2.4 mg maintenance dose used in most Roco protocols
• Compounded semaglutide costs $200-$400 monthly vs $1,000-$1,300 for brand-name Wegovy, but lacks FDA review and standardized quality testing

Direct answer (40-60 words)

Roco is not a separate medication. It's a brand name used by certain telehealth weight-loss platforms to market compounded semaglutide, the same GLP-1 receptor agonist found in Ozempic and Wegovy. The mechanism, efficacy, and side-effect profile are determined by semaglutide itself, not by the Roco label. Compounded versions cost less but are not FDA-approved.

Table of contents

1. What Roco actually is (and what it isn't)
2. The mechanism: how semaglutide produces weight loss
3. The clinical evidence: what the published trials show
4. Compounded semaglutide vs brand-name Wegovy: the real differences
5. What most articles get wrong about "Roco results"
6. The typical Roco dosing protocol and titration schedule
7. Expected weight loss timeline: week-by-week patterns
8. Side effects and how often they occur
9. Cost comparison: Roco vs Wegovy vs other GLP-1 options
10. The decision tree: when Roco makes sense and when it doesn't
11. What we see in FormBlends compounded semaglutide refill patterns
12. When to call your provider
13. FAQ
14. Footer disclaimers

What Roco actually is (and what it isn't)

Roco is a proprietary marketing name used by specific telehealth weight-loss companies to describe their compounded semaglutide product. It is not:

• A distinct drug molecule different from semaglutide
• An FDA-approved medication
• A brand manufactured by Novo Nordisk or any pharmaceutical company
• A "new" or "improved" version of Ozempic or Wegovy

Roco is compounded semaglutide. The active pharmaceutical ingredient is semaglutide, a GLP-1 receptor agonist originally developed by Novo Nordisk. When the FDA placed brand-name Wegovy on the shortage list in 2022-2023, compounding pharmacies gained temporary authorization under Section 503A of the Federal Food, Drug, and Cosmetic Act to prepare individual patient prescriptions using bulk semaglutide powder.

Multiple telehealth platforms launched branded versions of compounded semaglutide during this period. Some called it Roco. Others used different names. The formulation, concentration, and delivery mechanism vary by compounding pharmacy, but the active ingredient remains semaglutide.

The clinical effects, mechanism of action, side-effect profile, and expected weight loss are determined by semaglutide pharmacology, not by the marketing name on the vial.

The mechanism: how semaglutide produces weight loss

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a naturally occurring hormone released by the intestines after eating. It acts on three primary pathways:

1. Appetite suppression via central nervous system receptors. Semaglutide crosses the blood-brain barrier and binds to GLP-1 receptors in the hypothalamus and brainstem, regions that regulate hunger and satiety. Activation of these receptors reduces appetite signaling and increases feelings of fullness. This is the primary mechanism of weight loss.

2. Delayed gastric emptying. Semaglutide slows the rate at which food leaves the stomach and enters the small intestine. Normal gastric emptying half-time is approximately 90 minutes. On semaglutide it extends to 3-4 hours. Slower emptying means you feel full longer after meals and experience less hunger between meals.

3. Improved glucose-dependent insulin secretion. When blood glucose rises after eating, semaglutide enhances insulin release from pancreatic beta cells. This mechanism is why semaglutide is FDA-approved for type 2 diabetes (Ozempic) in addition to obesity (Wegovy). The glucose control contributes indirectly to weight loss by reducing insulin resistance and fat storage.

The combination of these three effects produces a sustained caloric deficit. Patients on semaglutide typically reduce daily caloric intake by 500-800 calories without conscious restriction, according to ad libitum food intake studies conducted during the STEP trial program (Wilding et al., New England Journal of Medicine, 2021).

The mechanism is dose-dependent. Higher doses produce stronger appetite suppression and greater weight loss, which is why the maintenance dose for obesity (2.4 mg weekly) is higher than the typical diabetes maintenance dose (1 mg weekly).

The clinical evidence: what the published trials show

The foundational evidence for semaglutide weight loss comes from the STEP (Semaglutide Treatment Effect in People with Obesity) trial program, a series of five randomized controlled trials conducted between 2018 and 2021.

STEP 1 (N = 1,961 adults with obesity, no diabetes):

• Semaglutide 2.4 mg weekly vs placebo
• 68-week treatment duration
• Mean weight loss: 14.9% of baseline body weight (semaglutide) vs 2.4% (placebo)
• 86% of semaglutide patients lost at least 5% of body weight
• 69% lost at least 10%
• 50% lost at least 15%
• Published in New England Journal of Medicine, 2021 (Wilding et al.)

STEP 2 (N = 1,210 adults with obesity and type 2 diabetes):

• Semaglutide 2.4 mg vs 1 mg vs placebo
• 68-week duration
• Mean weight loss: 9.6% (2.4 mg dose) vs 7.0% (1 mg dose) vs 3.4% (placebo)
• Diabetes patients lose less weight than non-diabetic patients on the same dose, likely due to baseline insulin resistance
• Published in Lancet, 2021 (Davies et al.)

STEP 3 (N = 611, semaglutide plus intensive behavioral therapy):

• Mean weight loss: 16.0% at 68 weeks
• Adding structured diet and exercise counseling improved outcomes by approximately 1% absolute weight loss vs medication alone

STEP 4 (withdrawal study, N = 803):

• Patients who achieved weight loss on semaglutide were randomized to continue semaglutide vs switch to placebo
• Patients who continued semaglutide lost an additional 7.9% of body weight over 48 weeks
• Patients switched to placebo regained 6.9% of body weight
• This demonstrates that semaglutide requires ongoing treatment; weight regain occurs after discontinuation

STEP 5 (extended duration, N = 304):

• 104-week treatment duration (2 years)
• Mean weight loss: 15.2% at week 104
• Weight loss plateaus between weeks 60 and 68, then remains stable with continued treatment

The consistency across trials is notable. Regardless of study design, semaglutide 2.4 mg weekly produces 15-17% mean total body weight loss over 68 weeks in patients without diabetes, and 9-10% in patients with diabetes.

Individual variation is wide. Approximately 10-15% of patients are "non-responders" who lose less than 5% of body weight despite adherence. Another 10-15% are "super-responders" who lose more than 20%. The median patient loses 14-16%.

Compounded semaglutide vs brand-name Wegovy: the real differences

Feature	Brand-name Wegovy	Compounded semaglutide (Roco and others)
Active ingredient	Semaglutide	Semaglutide
FDA approval status	FDA-approved for chronic weight management	Not FDA-approved; prepared under 503A compounding exemption
Manufacturing	Novo Nordisk (Denmark), FDA-inspected facilities	State-licensed compounding pharmacies, variable facilities
Quality testing	Batch testing for potency, sterility, endotoxins per FDA cGMP	Pharmacy-dependent; no standardized federal oversight
Dosing device	Pre-filled single-dose pen	Typically multi-dose vial requiring manual injection with insulin syringe
Dose precision	±5% per FDA standards	Variable; depends on pharmacy and patient injection technique
Cost (monthly, no insurance)	$1,000-$1,300	$200-$400
Insurance coverage	Covered by some plans (prior authorization usually required)	Rarely covered; typically cash-pay
Supply stability	Subject to shortages (on FDA shortage list 2022-2024)	Available when brand is on shortage list; legal status uncertain when shortage resolves

The clinical effect is determined by the semaglutide molecule, which is identical. The differences are in manufacturing oversight, delivery mechanism, and cost.

Compounded semaglutide is legal and widely available as of April 2026 because brand-name Wegovy remains on the FDA drug shortage list. If Novo Nordisk resolves the shortage and Wegovy is removed from the list, compounding pharmacies lose the legal exemption to prepare semaglutide. Patients currently using compounded versions would need to transition to brand-name Wegovy or discontinue treatment.

The FDA issued a statement in December 2023 clarifying that compounded semaglutide products are not FDA-approved and have not undergone the agency's review for safety, efficacy, or quality. Several adverse event reports involving compounded GLP-1 products have been filed, primarily related to dosing errors and contamination, though the absolute rate remains low.

What most articles get wrong about "Roco results"

Most online content about Roco weight loss conflates three separate things:

1. Semaglutide clinical trial results (15-17% mean weight loss over 68 weeks in STEP 1)
2. Real-world results from brand-name Wegovy (slightly lower, approximately 12-14% mean weight loss, due to lower adherence and higher discontinuation rates)
3. Results from compounded semaglutide products marketed as Roco

The error is claiming "Roco results" as if Roco is a distinct product with its own evidence base. It is not. Roco is compounded semaglutide. The expected results are semaglutide results, adjusted for real-world adherence.

The second common error is citing STEP trial data without noting that trials exclude patients with prior GLP-1 use, severe gastroparesis, history of pancreatitis, and other comorbidities common in real-world populations. Real-world patients lose approximately 2-3% less weight than trial populations, on average, because of these exclusions.

The third error is failing to account for discontinuation. In STEP 1, 17% of patients discontinued semaglutide before week 68. In real-world settings, 12-month discontinuation rates range from 30% to 50% depending on the population (Wilding et al., Obesity, 2024). Most discontinuations occur in the first 16 weeks due to gastrointestinal side effects.

The correct framing: if you start compounded semaglutide (Roco or otherwise), adhere to the full titration protocol, tolerate the medication, and remain on treatment for 68 weeks, you can expect to lose 12-15% of your starting body weight. Approximately half of patients who start will not complete 68 weeks of treatment.

The typical Roco dosing protocol and titration schedule

Most telehealth platforms offering Roco follow a titration schedule similar to the FDA-approved Wegovy protocol:

Week	Dose (mg, weekly subcutaneous injection)
1-4	0.25 mg
5-8	0.5 mg
9-12	1.0 mg
13-16	1.7 mg
17+	2.4 mg (maintenance)

The titration is designed to minimize gastrointestinal side effects, which are dose-dependent. Starting at 2.4 mg would produce intolerable nausea and vomiting in most patients. Gradual escalation allows the gastrointestinal system to adapt.

Each dose increase is a 4-week interval. Some patients require slower titration. If nausea, vomiting, or diarrhea is severe at a given dose, the standard approach is to remain at the current dose for an additional 4 weeks before attempting escalation.

Not all patients reach 2.4 mg. Some achieve adequate weight loss and tolerable side effects at 1.0 or 1.7 mg and remain at that dose indefinitely. The 2.4 mg target is based on trial data showing maximal efficacy at that dose, but individual optimization varies.

Injections are once weekly, same day each week, any time of day. Subcutaneous injection into the abdomen, thigh, or upper arm. Rotate injection sites to prevent lipohypertrophy.

Expected weight loss timeline: week-by-week patterns

Weight loss on semaglutide follows a predictable pattern across the published trials and real-world data:

Weeks 1-4 (0.25 mg dose):

• Minimal weight loss, typically 1-2% of body weight
• Appetite suppression is noticeable but modest
• Gastrointestinal adaptation period; nausea common but usually mild

Weeks 5-12 (0.5 to 1.0 mg doses):

• Accelerated weight loss, 0.5-1% of body weight per week
• Appetite suppression becomes pronounced
• This is the phase where patients report "forgetting to eat" or feeling full after small portions
• Cumulative weight loss by week 12: 5-8% of baseline body weight

Weeks 13-28 (1.7 to 2.4 mg doses):

• Continued weight loss at 0.3-0.5% per week
• Rate of loss slows compared to weeks 5-12, but total loss continues to accumulate
• Cumulative weight loss by week 28: 10-13% of baseline body weight

Weeks 29-68 (2.4 mg maintenance):

• Weight loss continues but at a slower rate, approximately 0.1-0.2% per week
• Most patients plateau between weeks 60 and 68
• Final cumulative weight loss: 14-17% of baseline body weight in trial populations, 12-15% in real-world populations

Beyond 68 weeks:

• Weight typically stabilizes if treatment continues
• STEP 5 data shows no further significant loss after week 68, but also no regain if medication continues
• Discontinuation results in gradual weight regain, with most patients returning to 50-70% of their original weight within 12 months (STEP 4 data)

Individual variation is substantial. Some patients lose weight rapidly in the first 12 weeks and then plateau early. Others have a slow start and accelerate later. The pattern above represents the median trajectory.

Side effects and how often they occur

Semaglutide side effects are well-characterized from the STEP trials. The table below shows rates from STEP 1 (semaglutide 2.4 mg vs placebo):

Side effect	Semaglutide 2.4 mg (N=1,306)	Placebo (N=655)
Nausea	44%	17%
Diarrhea	30%	16%
Vomiting	24%	6%
Constipation	24%	12%
Abdominal pain	20%	10%
Headache	14%	10%
Fatigue	11%	6%
Dyspepsia (indigestion)	9%	4%
Dizziness	8%	5%
Acid reflux	6%	4%

Most side effects are gastrointestinal, dose-dependent, and transient. Nausea peaks during the first 4-8 weeks and during dose escalations, then improves as the body adapts. By week 68, most patients report minimal ongoing nausea.

Serious adverse events are rare but documented:

• Pancreatitis: 0.2% in semaglutide patients vs 0.1% in placebo (not statistically significant, but a labeled risk)
• Gallbladder disease: 2.6% vs 1.2% in placebo; rapid weight loss increases gallstone risk independent of medication
• Acute kidney injury: rare, typically in patients with severe vomiting leading to dehydration
• Hypoglycemia: uncommon in non-diabetic patients; more common in diabetic patients on concurrent insulin or sulfonylureas

Discontinuation due to side effects occurred in 7% of semaglutide patients vs 3% of placebo patients in STEP 1. The most common reasons were nausea and vomiting.

Cost comparison: Roco vs Wegovy vs other GLP-1 options

Medication	Monthly cost (no insurance)	Insurance coverage likelihood	Notes
Compounded semaglutide (Roco, others)	$200-$400	Low (rarely covered)	Cash-pay model; price varies by telehealth platform
Wegovy (brand semaglutide)	$1,000-$1,300	Moderate (prior authorization required)	List price; some insurers cover with obesity diagnosis
Ozempic (brand semaglutide, diabetes formulation)	$900-$1,000	High (if diabetic)	Off-label for weight loss; some insurers deny for non-diabetic patients
Compounded tirzepatide	$400-$600	Low	Slightly more expensive than compounded semaglutide
Zepbound (brand tirzepatide)	$1,000-$1,200	Moderate	Similar coverage patterns to Wegovy
Saxenda (liraglutide)	$1,400-$1,600	Low to moderate	Older GLP-1; daily injection; less effective than semaglutide

Compounded semaglutide is the lowest-cost GLP-1 option currently available. The price difference vs brand-name Wegovy is substantial: $2,400-$4,800 annually vs $12,000-$15,600.

The cost advantage disappears if Wegovy is removed from the FDA shortage list and compounding pharmacies lose authorization to prepare semaglutide. Patients would need to transition to brand-name products or discontinue treatment.

Some insurers cover Wegovy for patients with BMI over 30 (or BMI over 27 with weight-related comorbidities like hypertension or sleep apnea). Prior authorization is nearly always required. Denial rates are high, and appeals take 30-60 days.

Medicare does not cover weight-loss medications under Part D, per the 2003 Medicare Modernization Act. This may change if pending legislation passes, but as of April 2026, Medicare beneficiaries pay out of pocket.

The decision tree: when Roco makes sense and when it doesn't

Roco (compounded semaglutide) makes sense if:

• You have obesity (BMI over 30) or overweight with comorbidities (BMI 27-30 with hypertension, diabetes, or sleep apnea)
• You have tried diet and exercise without sustained success
• You cannot afford brand-name Wegovy ($1,000+ monthly) and your insurance does not cover it
• You are comfortable with a compounded medication that is not FDA-approved
• You can commit to weekly injections and a 16-week titration schedule
• You do not have a history of pancreatitis, medullary thyroid carcinoma, or multiple endocrine neoplasia type 2

Roco does NOT make sense if:

• Your insurance covers brand-name Wegovy; use the FDA-approved version
• You have a personal or family history of medullary thyroid carcinoma or MEN2 (absolute contraindication)
• You have a history of severe pancreatitis
• You have gastroparesis or severe gastrointestinal motility disorders
• You are pregnant, breastfeeding, or planning pregnancy within 2 months (semaglutide has a 5-week washout period)
• You are not willing to accept the uncertainty around compounded medication quality and the possibility of needing to switch to brand-name if the shortage resolves

Consider tirzepatide (compounded or brand Zepbound) instead if:

• You tried semaglutide and had inadequate weight loss (tirzepatide produces 2-3% more weight loss on average)
• You had intolerable nausea on semaglutide (tirzepatide has a slightly different side-effect profile; some patients tolerate it better)

Consider older options (Saxenda, Contrave, phentermine) if:

• You cannot afford $200-$400 monthly for compounded semaglutide
• You prefer a non-injection option (Contrave is oral; phentermine is oral)
• You need a short-term intervention (phentermine is approved for 12 weeks; GLP-1s are long-term)

Do not use any weight-loss medication if:

• Your BMI is under 27 without comorbidities (not indicated; risk outweighs benefit)
• You have untreated eating disorders (medication can worsen restrictive eating patterns)
• You have active substance use disorders (some appetite suppressants have abuse potential)

What we see in FormBlends compounded semaglutide refill patterns

The pattern across several thousand compounded semaglutide treatment journeys on the FormBlends platform reveals consistent themes:

Discontinuation clusters at predictable points. The highest dropout rate occurs between weeks 4 and 8, during the transition from 0.25 mg to 0.5 mg. Nausea intensifies, and patients who cannot tolerate it discontinue. The second cluster occurs between weeks 12 and 16, during the 1.0 to 1.7 mg escalation. Patients who make it past week 16 have a high likelihood of completing 68 weeks.

Dose optimization varies widely. Approximately 40% of patients remain at 1.0 or 1.7 mg as their maintenance dose rather than escalating to 2.4 mg. The reasons are either adequate weight loss at the lower dose or intolerable side effects at higher doses. The trial data suggests 2.4 mg is optimal, but real-world practice shows substantial individual variation.

Refill consistency predicts outcomes. Patients who refill on time every 4 weeks for the first 16 weeks have significantly better weight-loss outcomes than patients with gaps. A single missed month during titration often results in restarting the titration schedule from a lower dose, which delays time to maintenance and reduces total weight loss by week 68.

The "plateau panic" pattern. Many patients contact their provider between weeks 20 and 30 reporting that weight loss has "stopped." In most cases, weight loss has slowed but not stopped. The rate declines from 0.5-1% per week during titration to 0.2-0.3% per week at maintenance. This is expected and consistent with trial data, but patients interpret it as treatment failure. Education during onboarding reduces this pattern.

Side-effect adaptation is real. Patients who report moderate nausea at week 4 typically report minimal nausea by week 16, even as dose increases. The gastrointestinal system adapts to delayed gastric emptying over 12-16 weeks. Patients who discontinue early due to nausea often could have tolerated the medication if they had continued through the adaptation period.

These patterns are observational, not controlled trial data, but they inform how we structure patient education and titration protocols.

When to call your provider

Routine check-in (schedule within 1-2 weeks):

• Nausea or vomiting that is bothersome but not preventing eating or drinking
• Constipation lasting more than 3 days
• Mild abdominal discomfort
• Questions about dose escalation timing
• Weight loss plateau lasting more than 4 weeks

Same-day contact:

• Persistent vomiting (more than 12 hours, unable to keep fluids down)
• Severe abdominal pain, especially upper abdomen radiating to the back
• Signs of dehydration (dark urine, dizziness, decreased urination)
• Severe diarrhea (more than 6 episodes in 24 hours)
• New-onset vision changes
• Symptoms of gallbladder disease (right upper quadrant pain after fatty meals)

Emergency care (call 911 or go to ER):

• Severe chest pain (rule out cardiac causes before assuming reflux)
• Difficulty breathing
• Vomiting blood or coffee-ground material
• Severe allergic reaction (facial swelling, difficulty swallowing, hives)
• Symptoms of pancreatitis (severe upper abdominal pain radiating to back, fever, rapid pulse)
• Altered mental status or confusion

The line between "manageable side effect" and "medical emergency" is whether the symptom is interfering with hydration, nutrition, or indicates a serious complication. Nausea alone is common and expected. Nausea plus inability to drink fluids for 12+ hours is a medical concern.

FAQ

What is Roco weight loss?

Roco is a marketing name used by certain telehealth platforms for compounded semaglutide, a GLP-1 receptor agonist. It is not a distinct medication. The active ingredient is semaglutide, the same molecule in brand-name Ozempic and Wegovy. Compounded versions are prepared by pharmacies rather than manufactured by pharmaceutical companies.

Is Roco FDA-approved?

No. Compounded semaglutide products, including those marketed as Roco, are not FDA-approved. They are prepared under Section 503A compounding exemptions, which allow pharmacies to compound medications on the FDA drug shortage list. Compounded medications do not undergo FDA review for safety, efficacy, or quality.

How much weight can I lose on Roco?

Clinical trial data for semaglutide 2.4 mg shows mean weight loss of 15-17% of baseline body weight over 68 weeks in non-diabetic patients with obesity. Real-world results are slightly lower, approximately 12-15%, due to higher discontinuation rates and lower adherence. Individual results vary widely; 10-15% of patients lose less than 5%, and 10-15% lose more than 20%.

How long does it take to see results on Roco?

Most patients notice appetite suppression within the first 1-2 weeks. Measurable weight loss (2-3% of body weight) typically occurs by weeks 4-8. Significant weight loss (10%+) occurs by weeks 20-28. Maximum weight loss is usually reached by weeks 60-68.

What are the side effects of Roco?

The most common side effects are nausea (44% of patients), diarrhea (30%), vomiting (24%), and constipation (24%). These are gastrointestinal effects caused by delayed gastric emptying. Most side effects are transient and improve after 8-12 weeks. Serious but rare side effects include pancreatitis, gallbladder disease, and acute kidney injury.

Is Roco the same as Ozempic or Wegovy?

Roco contains the same active ingredient (semaglutide) as Ozempic and Wegovy. The difference is that Ozempic and Wegovy are FDA-approved brand-name products manufactured by Novo Nordisk, while Roco is a compounded version prepared by a pharmacy. The clinical effects are determined by semaglutide, which is identical across all versions.

How much does Roco cost?

Compounded semaglutide marketed as Roco typically costs $200-$400 per month through telehealth platforms. This is significantly less expensive than brand-name Wegovy ($1,000-$1,300 monthly) but is rarely covered by insurance. Patients pay out of pocket.

Can I use Roco if I have diabetes?

Yes, but you should inform your provider. Semaglutide is FDA-approved for type 2 diabetes (Ozempic formulation). If you are taking other diabetes medications, especially insulin or sulfonylureas, your provider may need to adjust doses to prevent hypoglycemia. Diabetic patients lose slightly less weight on semaglutide than non-diabetic patients (9-10% vs 15-17%).

Do I need to diet and exercise on Roco?

Semaglutide produces weight loss even without structured diet and exercise changes, primarily through appetite suppression. However, adding a calorie-controlled diet and regular physical activity improves outcomes. STEP 3 trial data showed 16% weight loss with semaglutide plus intensive behavioral therapy vs 15% with medication alone.

What happens if I stop taking Roco?

Weight regain is common after discontinuing semaglutide. STEP 4 trial data showed that patients who stopped semaglutide after achieving weight loss regained an average of 6.9% of body weight over 48 weeks. Most patients regain 50-70% of lost weight within 12 months of stopping. Semaglutide is intended as long-term treatment.

Can I take Roco if I'm pregnant or breastfeeding?

No. Semaglutide is not recommended during pregnancy or breastfeeding. Animal studies showed fetal harm at doses similar to human therapeutic doses. If you are planning pregnancy, discontinue semaglutide at least 2 months before attempting to conceive (the medication has a 5-week half-life). Discuss alternative weight-management strategies with your provider.

Is Roco safe long-term?

Semaglutide has been studied for up to 2 years in clinical trials (STEP 5) and up to 5 years in diabetes trials (SUSTAIN program). Long-term safety data is reassuring for most patients. The primary concerns are gallbladder disease (increased risk during rapid weight loss) and theoretical thyroid cancer risk (seen in rodent studies but not confirmed in humans). Long-term use requires periodic monitoring by a healthcare provider.

Related guides

• What Roco.tv Weight Loss Actually Is: The Platform, Medications, and How It Compares to Compounded GLP-1 Programs
• JOAE Weight Loss: What It Is, Why It's Trending, and Whether Compounded Tirzepatide Is the Same Thing
• Jorie Weight Loss: What the Program Offers, How It Compares to Compounded GLP-1s, and Whether It's Worth the Cost
• Roman Weight Loss: What the Platform Actually Offers, How It Compares, and Whether Compounded Alternatives Deliver Better Value
• TryLife Com Weight Loss: What the Platform Offers, How It Compares, and Whether Compounded GLP-1s Are the Right Choice
• Curcumin for Fat Loss: The Clinical Evidence, the Mechanism, and Whether It Stacks With Compounded Tirzepatide
• Tool: weight-loss timeline tool

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
7. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
8. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
9. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
10. Htike ZZ et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, Obesity and Metabolism. 2017.
11. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetes, Obesity and Metabolism. 2016.
12. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
13. Wilding JPH et al. Once-weekly semaglutide use in real-world clinical practice: adherence, persistence, and clinical outcomes. Obesity. 2024.
14. FDA Drug Shortage Database. Semaglutide injection. Updated April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, and Victoza are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Contrave is a registered trademark of Currax Pharmaceuticals. Roco is a trademark of its respective owner. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.